IFN-EU 3ml vial №5 bottle

Active ingredient

1 vial contains 1 million, 3 million or 5 million IU of Interferon alfa-2a.
on 1 ml in an ampoule, 5 or 10 pieces. packaged.
REAFERON-EC-LIPINT freeze-dried powder for oral administration
1 bottle contains 50,000 IU of interferon alpha-2a, enclosed in liposomes; Vitamins E 10 mg and Vitamin C 1.5 mg.
on 1 ml in a bottle, 5 or 10 bottles in packing.

REAFERON-EU - №000642 / 01, 30.12.2003
REAFERON-EC-LIPINT - №000821 / 01-2001, 16.11.2001

The preparation of interferon alpha-2 recombinant human - Reaferon EC - is obtained by biosynthesis in the process of cultivation of bacterial producing strains (respectively Pseudomonas putida and E. coli), in whose genetic apparatus the human leukocyte interferon alpha-2 is integrated. Interferon alpha-2 recombinant is released from the obtained biomass containing protein, which is purified by reprecipitation, centrifugation, chromatography using effective adsorbents and final sterilizing filtration using membrane technology. At all stages of production, control is carried out using modern physicochemical methods. The final product (substance) is a highly purified interferon alpha-2 (at least 95% by monomer) in sodium chloride solution of 0.9% with an activity of at least 1.7 * 10⁷ IU / ml.
EU reaferon - a dry preparation for injections, is obtained by freeze drying a substance with a certain activity, to which human albumin is added as a stabilizer of biological activity in an amount of not more than 5 mg / ml, which withstood the control by an immunoenzyme method (sensitivity 0.5-1.0 ng) for the absence of HBs antigen and antibodies to the AIDS virus, and phosphate buffered saline.
IFN-EU-Lipint the world's only oral interferon alpha-2. Interferon in its pure form can not be taken orally, as it easily disintegrates under the action of enzymes in the stomach. IFN-EU-Lipint is enclosed in liposomes that protect it from destruction in the body.
IFN-EC-Lipint enters the body in the most natural way - through the mouth. Non-traumatic drug administration is very important in the treatment of children. Provides long-term interferon in the blood. The shell of the liposome is resistant to the aggressive environment of the stomach and the gastrointestinal tract. The interferon enclosed in the liposome passes through the gastrointestinal tract almost completely, enters the liver, is absorbed into the blood, and begins to slowly, gradually release. When taking Lipint, the content of its own interferon in the body is 100% higher than with the introduction of injectable Reaferon-EU. Most suitable for emergency prevention of colds and flu. Prophylactic administration of Lipint more than 2 times reduces the likelihood of the disease. There is no risk of transmitting dangerous viral infections with the needle (AIDS, hepatitis).
The composition IFN-EU Lipinta includes antioxidants - vitamins E and C. It has been established that the use of interferon together with vitamins E and C enhances the antiviral effect of interferon 14 times. When interferon and antioxidants (vitamins E and C) are used together in the treatment of children, the toxic effect of IFN on a growing body is neutralized.

Mechanism of action

It has antiviral, immunomodulatory and antitumor activity.

Indications and usage

Apply IFN with viral and neoplastic diseases.
The drug is effective in viral hepatitis. Prescribe for adults in the treatment of acute viral hepatitis B. The drug is most effective at the beginning of the icteric period before the 5th day of illness. With developed hepatic coma and cholestatic hepatitis, the drug is not very effective.
Applied with viral conjunctivitis, keratoconjunctivitis, keratitis, uveitis, as well as with hair-cell leukemia, chronic myeloid leukemia, kidney cancer. There is also evidence of the use of reaferon in the treatment of multiple sclerosis.

Contraindications

Allergic diseases, pregnancy (insufficient number of observations). Hemodynamic control is necessary in patients with cardiovascular diseases (periodic ECG registration). Individual intolerance to interferon.

Dosage and administration

REAFERON-EC-LIPINT is prescribed intramuscularly, subconjunctivally and topically.
For intramuscular administration The contents of 1 ampoule are dissolved immediately before use in 1 ml of isotonic sodium chloride solution.
In acute hepatitis B, enter 1 000 000 IU of reaferon 2 times a day for 5 to 6 days, then for 5 days 1 000 000 IU once a day. If necessary, continue to enter 1,000,000 IU 2 times a week for 2 weeks. The total dose of reaferon for a course of treatment is 15,000,000 to 20,000,000 IU.
With hairy cell leukemia administered daily 3,000,000 6,000,000 IU for 2 months. Maintenance therapy - 3 000 000 IU 2 times a week. During the course of treatment 420,000,000 - 600,000,000 IU.
With kidney cancer (stage IV) enter reaferon 3 000 000 IU daily for 10 days. Courses (3–9 and more) are repeated at intervals of 3 weeks. The total amount of the drug ranges from 90,000,000 to 270,000,000 IU or more.
With multiple sclerosis enter 1 000 000 IU 3 times a day with pyramidal syndrome and 1 - 2 times a day - with cerebellar. Enter for 10 days, then reduce the number of injections: in the same dose 1 time per week for 5 - 6 months.
In ophthalmic practice apply reaferon in the form of subconjunctival injections and locally, in the form of eye drops. For subconjunctival administration and instillation, the contents of 1 ampoule are dissolved in 5 ml of isotonic sodium chloride solution.
Subconjunctival administered with stromal keratitis and keratoiridocyclitis 60,000 IU in 0, 3 ml daily or every other day, depending on the severity of the process. The course of treatment is 15-25 injections, which are carried out under local anesthesia with a 0.5% solution of dikain. With conjunctivitis and superficial keratitis instill 2 drops of the solution into the conjunctival sac of the affected eye, starting from 6 to 8 times a day, then 3 to 4 times a day. The course of treatment is about 2 weeks.

REAFERON-EC-LIPINT is taken orally, 30 minutes before meals. Immediately before use, add 1-2 ml of distilled or cooled boiled water to the contents of the vial. With shaking for 1-5 minutes a homogeneous white suspension should form.
Acute hepatitis B: adults and children of school age - 1 million IU 2 times a day, for children 3-7 years old - 0.5 million IU 1 time per day for 10 days, if necessary (after follow-up biochemical blood tests) and more, until complete recovery.
Chronic hepatitis B (in active and inactive replicative forms associated with glomerulonephritis): school children and adults - 1 million IU, children 3-7 years old - 0.5 million IU for 10 days, 2 times a day and then for 1 month every other day once a day for a night.

When Reaferon is used, chills, general malaise, fever, skin allergic reactions (rash, itching), leuco-and thrombocytopenia are possible. With pronounced side effects, the injections are stopped. When applied topically, irritation of the conjunctiva, isolated follicles, and conjunctival edema are observed.

Special notes

Like all interferons, in individuals with prolonged use of the drug can cause the appearance of antibodies to interferon, which leads to a decrease in therapeutic effect.The use of the drug in viral hepatitis B at a later date is less effective. Not effective in developing hepatic coma and cholestatic disease. In patients with the erythrodermic stage of the fungoid mycosis, when the temperature rises above 39 degrees C and in the event of an exacerbation of the process, the administration of Reaferon-EC should be stopped. In persons with a high pyrogenic reaction (39 degrees C and above), the administration of Reaferon-EC is recommended for simultaneous use of Indomethacin . In case of storing the solution for topical use, it is necessary, following the rules of asepsis and antiseptics, to transfer the contents of the ampoule into a sterile vial and store the solution in a refrigerator at 4-10 degrees C for no more than 12 hours. -3 times a week. With pronounced local and general adverse reactions, the administration of Reaferon-EC should be discontinued.

:
List B. At a temperature of + 4 ° C to + 10 ° C.